Abstract: PO0522
Rates of Clinical Events in Patients with CKD: A UK Population-Based Cohort Study
Session Information
- CKD Health Services Research
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Abdul Sultan, Alyshah, AstraZeneca, Cambridge, United Kingdom
- Sun, Ping, AstraZeneca, Cambridge, United Kingdom
- Hedman, Katarina, AstraZeneca, Gothenburg, Sweden
- Wang, Xia, AstraZeneca, Gaithersburg, Maryland, United States
- Houser, Mark T., AstraZeneca, Gaithersburg, Maryland, United States
- Little, Dustin J., AstraZeneca, Gaithersburg, Maryland, United States
- James, Glen, AstraZeneca, Cambridge, United Kingdom
Background
Epidemiology of clinical event rates in patients with chronic kidney disease (CKD) is limited and can impede the ability of dialysis organizations, government agencies, other institutions, and payers to counsel patients and assess quality of care.
Methods
The Clinical Practice Research Datalink (CPRD) is a large, longitudinal UK-based primary care database that covers 6% (~4 million people) of the population. CPRD is linked to Hospital Episode Statistics (HES), which contains information on all hospital admissions in England. We identified CKD patients with eGFR <60 ml/min/1.73m2 in CPRD between 2004 and 2017. Adverse clinical events were identified using ICD-10 and READ codes. Non-dialysis dependent (NDD) patients were staged by eGFR. Dialysis dependent (DD) patients were identified using Classification of Interventions and Procedures (OPCS) and READ codes. Clinical events were identified by ICD10 and READ codes. Incidence rates per 100 person-years (PY) were calculated for selected adverse event stratified by dialysis status and CKD stage.
Results
We identified 310362 NDD and 5248 DD patients with a mean (standard deviation [SD]) age of 75.5 (10.2) years and a median (interquartile range [IQR]) follow-up of 87.5 (46.5-130.9) months. Among NDD patients 96%, 3%, and 1% of patient-years came from CKD 3, 4, and 5, respectively. Most event rates were consistently higher in DD CKD patients, compared to NDD CKD patients; and higher among CKD 4/5 compared to CKD 3 patients (Table 1).
Conclusion
Our results help establish baseline rates of specific clinical events and provide additional evidence of increased morbidity for DD vs. NDD patients, and for NDD patients with more severe vs. less severe kidney disease.
Funding
- Commercial Support –